Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

1.310 +0.010 (+0.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 Next >
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
From Cellectis Inc.
Via GlobeNewswire
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
From Cellectis Inc.
Via GlobeNewswire
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
From Cellectis Inc.
Via GlobeNewswire
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
BALLI-01 (evaluating UCART22) abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL population 
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
From Cellectis Inc.
Via GlobeNewswire
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Cellectis Inc.
Via GlobeNewswire
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
From Cellectis Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.